Content about Tris Pharma

June 20, 2013

Tris Pharma has hired a former buyer from AmerisourceBergen to head its generic drug business, the company said.

MONMOUTH JUNCTION, N.J. — Tris Pharma has hired a former buyer from AmerisourceBergen to head its generic drug business, the company said.

Tris announced the appointment of Janet Penner as president of the new generic pharmaceuticals business, which will have its own sales, marketing and distribution and will be responsible for bringing drugs to market. So far, the Food and Drug Administration has approved 13 of Tris' generics, including several first-to-market products.

April 3, 2013

The Food and Drug Administration has approved a new drug for allergies in children made by Tris Pharma, the drug maker said.

MONMOUTH JUNCTION, N.J. — The Food and Drug Administration has approved a new drug for allergies in children made by Tris Pharma, the drug maker said Wednesday.

Tris announced the approval of Karbinal ER (carbinoxamine maleate) extended-release oral suspension in the 4 mg-per-five milliliter strength. The company said the drug was the first sustained-release histamine receptor blocking agent for seasonal and perennial allergic rhinitis in children 2 and older.

August 28, 2012

Perrigo and Tris Pharma have launched a private-label version of Delsym extended-release oral liquid suspension containing dextromethorphan polistirex.

ALLEGAN, Mich., and MONMOUTH JUNCTION, N.J. — Perrigo and Tris Pharma have launched a private-label version of Delsym extended-release oral liquid suspension containing dextromethorphan polistirex.

The comapnies said the product, which is indicated for the temporary treatment of cough due to minor throat and bronchial irritation, will be marketed under major U.S. retailer and wholesalers' store brands or own label brands.

May 31, 2012

Tris Pharma on Thursday announced that the Food and Drug Administration has approved its generic equivalent to Reckitt Benckiser's Delsym, an extended-release oral liquid suspension containing dextromethorphan.

MONMOUTH JUNCTION, N.J. — Tris Pharma on Thursday announced that the Food and Drug Administration has approved its generic equivalent to Reckitt Benckiser's Delsym, an extended-release oral liquid suspension containing dextromethorphan.

June 29, 2011

A specialty pharmaceutical company has appointed a new VP human resources.

MONMOUTH JUNCTION, N.J. — A specialty pharmaceutical company has appointed a new VP human resources.

Cheryl Patnick, who has more than 20 years of experience in human resources and mergers/acquisitions, will lead and manage Tris Pharma's human resource activities, the company said Wednesday.

March 29, 2011

Tris Pharma on Tuesday announced its relaunch of the MyKidz Iron product line, which includes two supplement products and one prescription-only product.

MONMOUTH JUNCTION, N.J. — Tris Pharma on Tuesday announced its relaunch of the MyKidz Iron product line, which includes two supplement products and one prescription-only product.

MyKidz Iron was launched in 2007 by NextWave Pharmaceuticals. In August 2010, NextWave partnered with Tris on developing medicines focused on the central nervous system. As part of that partnership, all non-CNS over-the-counter products were acquired by Tris.

March 9, 2011

The Food and Drug Administration has accepted a regulatory approval application from Tris Pharma for a drug to treat allergies in children ages 2 years and older, Tris said Wednesday.

MONMOUTH JUNCTION, N.J. — The Food and Drug Administration has accepted a regulatory approval application from Tris Pharma for a drug to treat allergies in children ages 2 years and older, Tris said Wednesday.

Tris said that if approved, its carbinoxamine extended-release oral suspension would provide an alternative to currently available immediate-release formulations.

October 4, 2010

The Food and Drug Administration has approved a generic treatment for cough and upper respiratory...

WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved a generic treatment for cough and upper respiratory symptoms resulting from colds and allergies made by Par Pharmaceutical and Tris Pharma, Par said Tuesday.

The FDA approved hydrocodone polistirex and chlorpheniramine polistirex extended-release oral suspension. The drug is a generic version of UCB’s Tussionex, which has annual sales of around $226 million, according to IMS Health.

 

May 5, 2010

Perrigo on Wednesday announced that it has acquired the exclusive U.S. store brand rights to...